HR and breast cancer: Yamaguchi et al. [22] investigated the relationship between the kinetic curve pattern and molecular subtypes and showed that HR+/HER2− and triple-negative (TN) breast cancer subtypes demonstrated less washout on the delayed phase of enhancement compared with HER2–luminal (HR+/HER2+) and HER2-enriched (HR−/HER2+) subtypes.